Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.

abstract：:The natural history of squamous cell head and neck cancer is well understood. Locoregional approaches to salvage therapy for this disease have curative potential, primarily because distant metastases are uncommon. Before proceeding with salvage treatment, however, clinicians should identify the extent of disease and d...

journal_title：Seminars in oncology

authors： Adelstein DJ

更新日期：1994-08-01 00:00:00

abstract：:Lung cancer is the number one cause of cancer-related death in both men and women in the United States. Non-small cell lung cancer accounts for approximately 85% of these cases. Despite complete resection, long-term survival for patients with operable disease remains poor. Studies exploring postoperative chemotherapy ...

journal_title：Seminars in oncology

authors： Pisters KM

更新日期：2001-08-01 00:00:00

abstract：:Many cytotoxic therapies are available for patients with metastatic breast cancer, but response rates are low and acquired or de novo resistance is virtually universal. Among the agents that are used in the treatment of pretreated metastatic breast cancer are vinorelbine, gemcitabine, nab-paclitaxel, pemetrexed, plati...

journal_title：Seminars in oncology

authors： Cobleigh MA

更新日期：2011-06-01 00:00:00

abstract：:Bendamustine has clinical potential in the treatment of low-grade non-Hodgkin's lymphoma (NHL). As a single agent, bendamustine has been used in two studies in patients with relapsed or refractory low-grade NHL. When bendamustine 120 mg/m(2) was given on days 1 and 2, the overall response rate was 73% with complete re...

journal_title：Seminars in oncology

authors： Rummel MJ,Mitrou PS,Hoelzer D

更新日期：2002-08-01 00:00:00

abstract：:Remarkable strides have been made in the management of infectious complications after bone marrow transplantation. Improved understanding of patterns of infection, the introduction of new antimicrobials, the advent of cytokines to enhance immune recovery, the development of better strategies to control graft-versus-ho...

journal_title：Seminars in oncology

authors： Wingard JR

更新日期：1993-10-01 00:00:00

abstract：:Improving local tumor control is a goal of modern radiotherapy that will directly impact a majority of cancer patients. Numerous attempts to develop radiosensitizing agents have, however, met with limited clinical success. Recent advances in gene therapeutic approaches have allowed researchers to combine gene therapy ...

journal_title：Seminars in oncology

authors： Advani SJ,Chmura SJ,Weichselbaum RR

更新日期：1997-12-01 00:00:00

abstract：:Gene therapy has now become a standard experimental approach for treating cancers that have failed conventional therapies. As the understanding of the molecular nature of carcinogenesis develops, new approaches are being taken to directly target tumor cells, thus bypassing the difficulties of killing cells that are re...

journal_title：Seminars in oncology

authors： Freeman SM,Whartenby KA,Freeman JL,Abboud CN,Marrogi AJ

更新日期：1996-02-01 00:00:00

abstract：:Conventional cytogenetic studies have shown that the clinical and biological diversity of acute myeloid leukemia (AML) can be attributed, in part, to distinct chromosome aberrations, several of which are now routinely used for diagnosis, risk stratification, and outcome prediction. Although chromosome banding analysis...

journal_title：Seminars in oncology

authors： Bullinger L,Fröhling S

更新日期：2012-02-01 00:00:00

abstract：:Thus far the development of adjuvant therapies in melanoma has suffered greatly from the lack of effective drugs in stage IV melanoma. Chemotherapy, cytokines, vaccines, and combinations of drugs have been used with minimal success. This has led to adjuvant therapies that are not used uniformly or widely because of th...

journal_title：Seminars in oncology

authors： Eggermont AM,Testori A,Maio M,Robert C

更新日期：2010-10-01 00:00:00

abstract：:Currently, the primary use of liver transplantation in the setting of malignancy is in patients with hepatocellular carcinoma, with generally accepted criteria for transplantation consisting of the presence of one nodule less than 5 cm or two of three nodules each less than 3 cm in the absence of detectable vascular i...

journal_title：Seminars in oncology

authors： Belghiti J

更新日期：2005-12-01 00:00:00

abstract：:Skin findings can serve as a clue to internal disease. In this article, cutaneous manifestations of underlying lung malignancy are reviewed. Paraneoplastic dermatoses are rare, but when recognized early, can lead to early diagnosis of an underlying neoplasm. Malignancy-associated dermatoses comprise a broad group of h...

journal_title：Seminars in oncology

authors： Owen CE

更新日期：2016-06-01 00:00:00

abstract：:Data from women with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III or IV) were analyzed to evaluate the pharmacokinetic/pharmacodynamic relationships of carboplatin-based combination chemotherapy. With the equation area under the plasma concentration versus time curve (AUC) =...

journal_title：Seminars in oncology

authors： Egorin MJ,Reyno LM,Canetta RM,Jodrell DI,Swenerton KD,Pater JL,Burroughs JN,Novak MJ,Sridhara R

更新日期：1994-10-01 00:00:00

abstract：:Among the various deleterious effects of cancer chemotherapy, vascular toxicity is the least well recognized. This lack of recognition may be because the vasculotoxic phenomena are not unique to antineoplastic agents, can occur in patients without exposure to these agents, and the fact cancer itself may produce a hype...

journal_title：Seminars in oncology

authors： Shahab N,Haider S,Doll DC

更新日期：2006-02-01 00:00:00

abstract：:A phase II study was performed to investigate the tolerance and efficacy of the combination of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and gemcitabine in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). To date, 24 patients (five with stage IIIB and 19 with stage IV NSCLC...

journal_title：Seminars in oncology

authors： Georgoulias V,Kourousis C,Androulakis N,Kakolyris S,Dimopoulos MA,Bouros D,Papadimitriou C,Hatzakis K,Heras P,Kalbakis K,Kotsakis T,Vardakis N,Meramveliotakis N,Hatzidaki D

更新日期：1997-08-01 00:00:00

abstract：:Platelet-derived microparticles (PMPs) represent the most abundant microparticle (MP) subtype. Their presence reflects platelet activity, physiopathology, and the thrombotic state of cancer patients. The quantity and composition of PMPs strictly depends on the way MPs were generated. Because platelets play a key role ...

journal_title：Seminars in oncology

authors： Mezouar S,Mege D,Darbousset R,Farge D,Debourdeau P,Dignat-George F,Panicot-Dubois L,Dubois C

更新日期：2014-06-01 00:00:00

abstract：:90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients wit...

journal_title：Seminars in oncology

authors： Gordon LI

更新日期：2003-12-01 00:00:00

abstract：:One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activates multiple signaling cascades that promote carcinogenesis and immune evasion. Therefore, these molecules have been extensively targeted in cancer immunotherapy. Beyond EGFR signaling cascade inhibition, some of these agen...

journal_title：Seminars in oncology

authors： Mazorra Z,Chao L,Lavastida A,Sanchez B,Ramos M,Iznaga N,Crombet T

更新日期：2018-01-01 00:00:00

abstract：:Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has shown in vitro and clinical activity against non-small cell lung cancer and astrocytic brain tumors, tumors traditionally thought of as relatively resistant to chemotherapy and radiotherapy. Because of its ability to block dividing cells in the G2/M p...

journal_title：Seminars in oncology

authors： Glantz MJ,Choy H,Akerley W,Kearns CM,Egorin MJ,Rhodes CH,Cole BF

更新日期：1996-12-01 00:00:00

abstract：:The treatment of locally advanced carcinoma of the cervix with radiation therapy as a single modality is inadequate, specifically for stage III and IVA disease. While chemotherapy as single-modality therapy is ineffective in advanced cervical cancer, there is some evidence of efficacy when used in combination with rad...

journal_title：Seminars in oncology

authors： Wadler S,Goldberg G,Fields A,Anderson P,Beitler JJ,Sood B,Haynes H,Runowicz C

更新日期：1996-08-01 00:00:00

abstract：:Constitutive expression of interferons (IFNs) and activation of their signaling pathways have pivotal roles in host responses to malignant cells in the tumor microenvironment. IFNs are induced by the innate immune system and in tumors through stimulation of Toll-like receptors (TLRs) and through other signaling pathwa...

journal_title：Seminars in oncology

authors： Cheon H,Borden EC,Stark GR

更新日期：2014-04-01 00:00:00

abstract：:The effectiveness of current chemotherapeutic approaches for the treatment of solid tumors has reached a near plateau, suggesting we are nearing the limit of cytoreduction. It is hypothesized that this may be due to "subset effect," and that drugs administered according to responses predicted for particular subgroups ...

journal_title：Seminars in oncology

authors： Paik S

更新日期：2001-06-01 00:00:00

abstract：:In the United States there are approximately 100,000 women living with metastatic breast cancer. Bone is the most common site of breast cancer metastases and it is estimated that up to 85% of patients dying from this disease have developed osseous involvement. Skeletal metastases are often associated with dangerous an...

journal_title：Seminars in oncology

authors： Van Poznak C

更新日期：2001-08-01 00:00:00

abstract：:The limited single-agent activity of cisplatin, its toxicity profile, and the inconvenience involved in hydrating patients has compelled researchers to investigate other treatments as possible alternative therapies in non-small cell lung cancer. More recently, interest has focused on the potential of nonplatinum combi...

journal_title：Seminars in oncology

authors： Georgoulias V,Scagliotti G,Miller V,Eckardt J,Douillard JY,Manegold C

更新日期：2001-02-01 00:00:00

abstract：:Over 50% of patients with small cell lung cancer (SCLC) will develop symptomatic brain metastases during the course of their disease. Results of whole brain radiotherapy, the standard treatment, are rather poor and relapses are frequent. Thus, new modes of therapy are urgently needed for these patients. In this study,...

journal_title：Seminars in oncology

authors： Postmus PE,Smit EF,Berendsen HH,Sleijfer DT,Haaxma-Reiche H

更新日期：1992-04-01 00:00:00

abstract：:We report the updated results of an intensive treatment protocol for children (< 18 years) and adults (> or = 18 years) with advanced B-cell lymphomas. The protocol consists of two chemotherapy regimens: A, consisting of cyclophosphamide, doxorubicin, vincristine and high-dose methotrexate (CODOX-M), and B, consisting...

journal_title：Seminars in oncology

authors： Adde M,Shad A,Venzon D,Arndt C,Gootenberg J,Neely J,Nieder M,Owen W,Seibel N,Wilson W,Horak ID,Magrath I

更新日期：1998-04-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00

abstract：:Cyclooxygenase (COX) enzyme-dependent arachidonic acid metabolites occupy key positions in important physiologic processes such as immunity, reproduction, and vascular integrity. Large retrospective and prospective population-based studies have shown that the use of both nonselective, nonsteroidal anti-inflammatory dr...

journal_title：Seminars in oncology

authors： Stoehlmacher J,Lenz HJ

更新日期：2003-06-01 00:00:00

abstract：:Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reag...

journal_title：Seminars in oncology

authors： Ferry-Galow KV,Makhlouf HR,Wilsker DF,Lawrence SM,Pfister TD,Marrero AM,Bigelow KM,Yutzy WH,Ji JJ,Butcher DO,Gouker BA,Kummar S,Chen AP,Kinders RJ,Parchment RE,Doroshow JH

更新日期：2016-08-01 00:00:00

abstract：:Diffuse large B-cell lymphoma (DLCL) is the most frequently diagnosed subtype of non-Hodgkin's lymphoma (NHL), and more than 50% of cases present in patients over 60 years of age. Although cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) is currently regarded as the gold standard treatment for DLCL, less tha...

journal_title：Seminars in oncology

authors： Coiffier B

更新日期：2002-04-01 00:00:00

abstract：:Selective aromatase inhibitors cause regression of breast carcinomas by reducing estrogen production via inhibition of the enzyme aromatase (estrogen synthetase). A higher incidence of hormone-dependent breast cancer occurs in postmenopausal women than in younger women. Thus, total estrogen blockade is more likely to ...

journal_title：Seminars in oncology

authors： Brodie AM,Njar VC

更新日期：1996-08-01 00:00:00